Physician profile
Mohit Jindal
NPI 1063619658
$10,442.71
in general payments reported to CMS, 2019-2025
38 companies · $1,775 in 2025
The $1,775 reported for 2025 was more than what 76% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $488 · 2021: $1,060 · 2022: $1,565 · 2023: $2,406 · 2024: $2,532 · 2025: $1,775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,617 · Education: $95.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,616.70 |
| Education | $95.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,661.86 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,213.80 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,102.22 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $958.83 | 2019-2025 | Stelara, Tremfya |
| Genzyme Corporation | $475.27 | 2022-2025 | |
| Ardelyx, INC. | $365.71 | 2022-2025 | Ibsrela |
| Merck Sharp & Dohme LLC | $328.21 | 2019-2024 | Dificid |
| Pfizer INC. | $283.97 | 2023-2025 | |
| Qol Medical, LLC | $278.90 | 2022-2025 | Sucraid, Sucraid |
| Celgene Corporation | $225.70 | 2021-2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $144.61 | 2020-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $125.15 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $121.51 | 2021-2023 | |
| Ferring Pharmaceuticals INC. | $96.20 | 2023-2024 | Rebyota |
| Ipsen Biopharmaceuticals, INC | $93.25 | 2024-2025 | Iqirvo |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $85.00 | 2024 | |
| Enterra Medical, INC. | $82.63 | 2023 | |
| Braintree Laboratories, INC. | $80.65 | 2021-2025 | Suflave, Sutab |
| Regeneron Healthcare Solutions, INC. | $78.61 | 2023-2025 | Dupixent |
| Pharmacosmos Therapeutics INC. | $70.03 | 2021-2022 | |
| Micro-Tech Endoscopy USA, INC. | $66.87 | 2025 | |
| Echosens North America, INC. | $62.25 | 2020 | |
| Shire North American Group INC | $62.17 | 2019 | |
| Celltrion USA INC. | $49.41 | 2024 | Zymfentra |
| Ucb, INC. | $46.19 | 2019 | |
| Mallinckrodt Hospital Products INC. | $35.26 | 2025 | Terlivaz |
| Intercept Pharmaceuticals, INC. | $35.23 | 2023 | Ocaliva |
| Alnylam Pharmaceuticals INC. | $31.18 | 2025 | Givlaari |
| Daiichi Sankyo INC. | $24.66 | 2024 | Injectafer |
| Amgen INC. | $24.66 | 2022 | |
| Madrigal Pharmaceuticals | $20.65 | 2024 | Resmetirom |
| Phadia US INC. | $18.75 | 2022 | |
| Organon LLC | $17.93 | 2025 | Hadlima, Renflexis |
| W. L. Gore & Associates, INC. | $16.68 | 2021 | |
| Alfasigma USA, INC. | $15.87 | 2020 | |
| Allergan, INC. | $15.53 | 2020 | |
| Lilly USA, LLC | $13.79 | 2023 | |
| Sandoz INC. | $13.52 | 2023 | Hyrimoz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohit Jindal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.